Stride Rite Children’s Group (SRCG) brings blockbuster summer movie excitement to kids with the all-new X-celeRacers™ by Stride Rite® Marvel collection. Premiering at locations where Stride Rite shoes are sold, X-celeRacers inspires kids to be super — to the Power of X — with styles featuring their favorite Marvel Super Heroes including Iron Man, Captain America, The Incredible Hulk and Spider-Man.
The new X-celeRacers sneaker features an X-tra fast strap with an adjustable closure for X-traordinary fit, X-Grip with a grooved outsole for X-treme traction, X-tra Flex with a lightweight outsole for X-ceptional agility and X-treme lightweight cushioning for comfort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56014-stride-rite-kids-x-celeracers-marvel-collection-power-of-x-imagination
Oura Health, the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5M€ after the closure of a round led by US-based Bold Capital Partners and Finland’s Tesi. The funding will be used to scale US market operations and push the Oura platform forward.
The Oura ring and app guides wearers towards better sleep, recovery and readiness to perform by analyzing the body’s sleep, activity levels, daily rhythms and physiological responses.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8362451-oura-health-strengthens-position-us-market/
Atlanta, GA - February 27th, 2019 - Ionic Security, the pioneer in data trust, today announced the closure of a $40 million strategic investment round led by clients and partners, and the addition of new leadership.
These announcements come swiftly on the heels of new partnership announcements with BigID, ReversingLabs, and the achievement of AWS Advanced Technology Partner and Public Sector Partner Status.
To view the multimedia release go to:
https://www.multivu.com/players/English/8498051-ionic-security-data-trust-funding-leadership/
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
Ethicon, Inc., a worldwide leader in surgical care, has announced its entrance into the barbed suture market with the launch of its new portfolio of STRATAFIX™ Knotless Tissue Control Devices, representing the next evolution in wound closure technology. With significantly more points of fixation than traditional sutures, STRATAFIX™ Devices give surgeons more consistent control over every pass (through the tissue), and combine the strength and security of interrupted closure with the efficiency of continuous closure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58405-ethicon-launches-stratafix-knotless-tissue-control-devices
Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.*
To view the multimedia release go to:
https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
